A Phase II, Double-blind, Randomized, Placebocontrolled, Parallel-group, Single-center Study to Evaluate the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in Multiple Sclerosis (MS) Patients With Spasticity-related Symptoms
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Phytotech
- 14 Sep 2017 Planned number of patients changed from 60 to 70.
- 14 Sep 2017 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
- 14 Sep 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.